OUR PORTFOLIO COMPANIES
As early stage investors, Mission Cure Capital expects above-market returns, but our life science portfolio companies are much more than investment opportunities.
As chronic pancreatitis patients, family members and impact investors, we fuel problem-solvers who share our urgency and measure success by improvements in disease progression and quality of life.
Regenerative Medical Solutions
MCC invested in RMS to advance treatments for all types of diabetes, starting with Type 3c. Less common than Type 1 or Type 2 diabetes, Type 3c diabetes, also referred to as “pancreatogenic” diabetes, results from a pancreatic condition such as chronic pancreatitis, cystic fibrosis, pancreatic cancer or a total pancreatectomy.